new Oral Antibiotic for Gonorrhea Approved by FDA
Table of Contents
A new kind of oral antibiotic to treat gonorrhea has secured Food and Drug Governance approval, the second time in two days that a new drug for the common sexually transmitted infection has come through licensure.
Neisseria gonorrhoeae, the bacterium that causes gonorrhea, has for decades been evolving to evade the antibiotics used to treat it. The current standard of care – an intramuscular injection of ceftriaxone – is the last antibiotic to reliably treat the infection, and increasingly treatment failures are being reported.
Zoliflodacin, which will be marketed under the name Nuzolvence, is the first new drug to uniquely target gonorrhea infections in decades, and the first developed as part of a public-private partnership.
The drug’s journey to market has been a long one, with multiple organizations playing a role. The license was issued to Entasis Therapeutics,which is now part of Innoviva Specialty Therapeutics,a manufacturer of drugs for infectious diseases and patients in critical care.
Innoviva and the Global Antibiotic Research and Growth Partnership, GARDP, a not-for-profit institution that strives to develop treatments for drug-resistant pathogens that are accessible worldwide, brought the drug through the final stage of testing and licensure.
“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development,” GARDP Executive Director Manica Balasegaram said in a statement.
“Zoliflodacin shows that a different public-private partnership approach to antibiotic development is possible – one that prioritizes global health needs, strengthens access where the burden is highest, and protects the effectiveness of new drugs for the long-term,” he said.
Innoviva will market the drug in North America and Western Europe, and GARDP will pursue efforts to have it approved in low- and middle-income countries.
Nuzolvence was approved for treatment of uncomplicated urogenital gonorrhea in individuals 12 years of age and older and weighing at least 77 pounds.
Its approval followed closely on the heels of the FDA’s granting of a supplemental
New Gonorrhea Treatment Nuzolvence Approved in Europe, Offers Hope Against Rising Resistance
the European Commission has approved a new treatment for gonorrhea, nuzolvence (cefiderocol), offering a crucial weapon in the fight against the sexually transmitted infection as antibiotic resistance continues to spread. While clinical trials showed promising results, definitive proof of efficacy against resistant strains was limited due to the relatively small number of such cases within the study population. Despite this, experts are optimistic that Nuzolvence will extend the timeline before gonorrhea becomes untreatable, and its unique mechanism of action may make it more durable against the development of resistance.
Understanding the Threat of Gonorrhea and Antibiotic Resistance
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is a growing public health concern. The World Health Organization (WHO) estimates https://www.who.int/news-room/fact-sheets/detail/gonorrhoea that approximately 87 million people contract gonorrhea each year globally.The bacteria are becoming increasingly resistant to existing antibiotics, making treatment more arduous and potentially leading to serious complications, including infertility, ectopic pregnancy, and increased risk of HIV infection.
the rise of antibiotic resistance occurs when bacteria evolve to survive exposure to drugs designed to kill them. Gonorrhea’s remarkable ability to adapt and develop resistance is a major challenge for public health officials. currently, there are limited new antibiotic options in development to combat this trend.
Nuzolvence: A New Approach to Gonorrhea Treatment
Nuzolvence, developed by Shionogi, represents a new class of antibiotics called siderophore cephalosporins. Unlike traditional antibiotics, cefiderocol delivers the antibiotic directly into the bacterial cell, bypassing many of the resistance mechanisms Neisseria gonorrhoeae has developed.https://www.shionogi.com/en/news/2024/03/20240315-cefiderocol.html
The approval is based on clinical trial data, including results from the CREST-1 trial. While the trials demonstrated clinical efficacy, Dr. Heidi Erickson, Director of Medical Sciences at GARDP (global Antibiotic Research and Development Partnership), noted that the number of infections caused by antibiotic-resistant strains within the trial wasn’t large enough to provide statistically significant proof of efficacy against those specific strains.
“we believe that this is clinically meaningful data,” Dr. Erickson told STAT News. https://www.statnews.com/2024/03/15/gonorrhea-treatment-nuzolvence-europe-approval/ “We’re hoping this data will be referred to during treatment guideline development in the future, and certainly will provide clinicians… some data on which to make clinical decisions about their patients.”
Hope for the Future, But Vigilance is Key
Experts acknowledge that the development of resistance is inevitable, but believe Nuzolvence may offer a longer period of effectiveness. Dr. Charles Hook, a leading researcher in gonorrhea treatment, believes the drug’s unique mechanism of action could make it more difficult for the bacteria to develop resistance.
“On one hand, development of resistance is an inexorable process for gonorrhea. It’s just always going to happen. Conversely,I think this drug is relatively resistant to development of resistance. And that’s a good thing,” hook stated.
However, continued surveillance and responsible antibiotic use are crucial to preserving the effectiveness of Nuzolvence and any future treatments. The approval of Nuzolvence buys valuable time, but it doesn’t eliminate the need for ongoing research and development of new antibiotics to combat this evolving threat.
Key Takeaways:
* New Treatment: Nuzolvence (cefiderocol) has been approved in Europe for the treatment of gonorrhea.
* Rising Resistance: Gonorrhea is becoming increasingly resistant to existing antibiotics, posing a significant public health challenge.
* Unique Mechanism: Nuzolvence uses a novel approach to deliver antibiotics directly into bacterial cells, potentially overcoming existing resistance mechanisms.
* Continued Vigilance: While promising, Nuzolvence is not a cure-all. Ongoing research, surveillance, and responsible antibiotic use are essential to combat gonorrhea and prevent further resistance.
Worth a look